Truvada®: Clinical Trials

16 trials of Truvada®, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

13 completed, 2 active not recruiting, 1 terminated. 16 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	16	Completed 13, Active not recruiting 2, Terminated 1

Follow Truvada®: new trials by email Literature Review of Truvada® trials Research Report on Truvada®

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN), F/TAF - Pre-Exposure Prophylaxis of HIV Infection	Phase 3	Active not recruiting	Gilead Sciences	5368	2021-08-30	2026-10-16
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN) - Pre-Exposure Prophylaxis of HIV Infection	Phase 3	Active not recruiting	Gilead Sciences	3292	2021-06-28	2026-10-06
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults B/F/TAF, Placebo to match DTG, Placebo to match F/TDF - HIV-1/HBV Co-Infection	Phase 3	Completed	Gilead Sciences	244	2018-05-30	2025-03-19
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection F/TAF, F/TDF, F/TAF Placebo - Pre-Exposure Prophylaxis of HIV-1 Infection	Phase 3	Terminated	Gilead Sciences	5399	2016-09-02	2026-09-08
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women E/C/F/TAF, E/C/F/TDF, ATV - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	472	2016-02-19	2020-03-04
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years E/C/F/TAF, TDF, FTC - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	167	2015-12-22	2020-03-04
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults RTV, ATV, DRV - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	578	2015-11-20	2020-12-29
Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy triple therapy, dual therapy - HIV	Phase 3	Completed	University Hospital, Tours	224	2014-12-01	2025-12-26
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF FTC/TDF, F/TAF, Allowed third antiretroviral agent - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	668	2014-05-06	2020-03-12
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF - HIV, HIV Infections	Phase 3	Completed	Gilead Sciences	1443	2013-03-27	2021-04-13
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women E/C/F/TDF, ATV, RTV - Acquired Immunodeficiency Syndrome, HIV Infections	Phase 3	Completed	Gilead Sciences	583	2012-10-24	2019-09-20
Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection raltegravir (Isentress), Truvada® - HIV Infections	Phase 3	Completed	Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux	149	2010-11-01	2017-02-23
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults COBI, RTV, ATV - HIV, HIV Infections	Phase 3	Completed	Gilead Sciences	698	2010-04-01	2016-05-23
Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine TDF, FTC/TDF, TDF Placebo - Hepatitis B	Phase 3	Completed	Gilead Sciences	280	2008-09-01	2016-03-11
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B TDF, ADV, TDF placebo - Chronic Hepatitis B	Phase 3	Completed	Gilead Sciences	266	2005-06-01	2017-03-09
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B TDF, ADV, TDF placebo - Chronic Hepatitis B	Phase 3	Completed	Gilead Sciences	382	2005-02-01	2017-03-07

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding